Abstract / Summary
Introduction: Alveolar echinococcosis is a chronic and potentially severe parasitic disease that often requires long-term treatment and is associated with considerable uncertainty regarding prognosis. These characteristics may contribute to significant psychological burden in affected individuals. The aim of this study was to assess the intensity of fear of disease progression among patients diagnosed with echinococcosis treated with different therapeutic approaches and to identify medical and psychosocial factors associated with higher levels of this fear. Method: A total of 35 patients with a diagnosis of alveolar echinococcosis participated in the study. Self-report questionnaires were used to measure anxiety, stress, and knowledge about the disease. Additional data were collected regarding the course of treatment and the nature of social responses after disclosure of the diagnosis. Results: A high level of fear of progression was reported by many patients—seven individuals rated their fear as maximal or near-maximal (9–10 on a 0–10 scale). Statistical analysis showed no significant associations between fear levels and medical variables such as treatment type, drug importation, or presence of side effects. However, a significant relationship was found between the intensity of fear and social reactions. Patients who experienced non-supportive or stigmatizing responses (e.g., shock, distancing, inappropriate comments) reported significantly higher levels of fear of progression compared to those who received support and understanding. Conclusions: Fear of disease progression may constitute a substantial psychological burden in patients with alveolar echinococcosis. In this sample, FoP was significantly associated with psychological and psychosocial variables, including negative social reactions, whereas no statistically significant associations were detected with the evaluated medical and treatment-related variables. These findings highlight the importance of considering the psychosocial context of AE and support the integration of psychological assessment and support into the clinical care of affected patients.